openPR Logo
Press release

Ocular Hypertension Pipeline Analysis, 2025 by DelveInsight | Santen Pharmaceutical, Nicox Ophthalmics, Inc., Allysta Pharmaceuticals, Qlaris Bio, Inc, Ripple Therapeutics, Laboratoires Thea, Ocular T

09-03-2025 12:32 AM CET | Associations & Organizations

Press release from: ABNewswire

Ocular Hypertension Pipeline Analysis

Ocular Hypertension Pipeline Analysis

DelveInsight's, "Ocular Hypertension - Pipeline Insight, 2025" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The Ocular Hypertension pipeline includes over 50 prominent companies actively developing more than 75 therapies for the treatment of ocular hypertension, according to DelveInsight.

Ocular Hypertension Overview:

Ocular hypertension is a condition characterized by elevated eye pressure due to improper drainage of the aqueous humor, the clear fluid that maintains eye shape and supports ocular health. While most individuals with ocular hypertension do not experience noticeable symptoms or vision changes, the condition increases the risk of developing glaucoma, which can damage the optic nerve and lead to vision loss. Not everyone with ocular hypertension will develop glaucoma, but regular monitoring by an eye care professional is essential for early detection and effective management. Lifestyle factors such as diet and stress can affect eye pressure, though some patients may require medication or other treatments to control it. Early intervention helps protect vision and prevent long-term damage.

Intraocular pressure can rise due to either increased fluid production or reduced drainage within the eye. Several underlying conditions can disrupt normal aqueous humor outflow, leading to elevated pressure. For example, uveitis-an inflammation of the eye's middle layer-can impede fluid drainage. Pigment dispersion syndrome, where tiny pigment granules from the iris circulate and block the trabecular meshwork, and pseudoexfoliation syndrome, involving the buildup of microscopic protein fibers, can both obstruct fluid flow. Additional contributing factors include eye tumors, large cataracts, prior trauma or surgery, and certain medications such as corticosteroids. Chronic angle-closure, where the iris blocks the drainage angle, can further restrict outflow and elevate eye pressure.

Download our report @ https://www.delveinsight.com/report-store/ocular-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

"Ocular Hypertension Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Ocular Hypertension Therapeutics Market.

Key Takeaways from the Ocular Hypertension Pipeline Report

*
DelveInsight's Ocular Hypertension pipeline report highlights a dynamic landscape, featuring over 50 active companies developing more than 75 therapies for Ocular Hypertension.

*
In December 2024, the FDA approved a generic latanoprost 0.005% ophthalmic solution from Gland Pharma Limited, indicated for lowering elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This generic has been confirmed as bioequivalent and therapeutically equivalent to the brand-name Xalatan.

*
In June 2024, the FDA granted De Novo classification to Balance Ophthalmics' FYSX Ocular Pressure Adjusting Pump. This innovative, non-pharmacological device is designed to reduce IOP during sleep in adults with open-angle glaucoma. The system combines a compact pump with pressure-sensing goggles, offering a novel way to manage nighttime IOP fluctuations.

*
Leading companies advancing the Ocular Hypertension treatment landscape include Santen Pharmaceutical, Nicox Ophthalmics, Allysta Pharmaceuticals, Qlaris Bio, Ripple Therapeutics, Laboratoires Thea, Ocular Therapeutix, Otsuka Beijing Research Institute, Alcon Research, AbbVie, Glaukos Corporation, MediPrint Ophthalmics, Ocuphire Pharma, and others.

*
Promising pipeline candidates under development include Sepetaprost, NCX 470, QLS-111, H-1337, RTC-1119, among others.

Ocular Hypertension Pipeline Analysis

The Ocular Hypertension pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Ocular Hypertension Market.

*
Categorizes Ocular Hypertension therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Ocular Hypertension drugs under development based on:

*
Stage of development

*
Ocular Hypertension Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Ocular Hypertension Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Ocular Hypertension Licensing agreements

*
Funding and investment activities supporting future Ocular Hypertension market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Ocular Hypertension Emerging Drugs

*
Sepetaprost: Santen Pharmaceutical

*
NCX 470: Nicox Ophthalmics, Inc.

*
QLS-111: Qlaris Bio, Inc.

*
H-1337: Allysta Pharmaceuticals

*
RTC-1119: Ripple Therapeutics

Ocular Hypertension Companies

Over 50 leading companies are actively developing treatments for ocular hypertension. Among them, Santen Pharmaceutical has a drug candidate that has reached the most advanced stage of development, preregistration.

DelveInsight's report covers around 75+ products under different phases of Ocular Hypertension clinical trials like

*
Ocular Hypertension Late stage Therapies (Phase III)

*
Ocular Hypertension Mid-stage Therapies (Phase II)

*
Ocular Hypertension Early-stage Therapies (Phase I)

*
Ocular Hypertension Pre-clinical and Ocular Hypertension Discovery stage Therapies

*
Ocular Hypertension Discontinued & Inactive Therapies

Ocular Hypertension pipeline report provides the Ocular Hypertension therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Ocular Hypertension Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Ocular Hypertension Therapies and Key Ocular Hypertension Companies: Ocular Hypertension Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/ocular-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Ocular Hypertension Pipeline Therapeutic Assessment

- Ocular Hypertension Assessment by Product Type

- Ocular Hypertension By Stage

- Ocular Hypertension Assessment by Route of Administration

- Ocular Hypertension Assessment by Molecule Type

Download Ocular Hypertension Sample report to know in detail about the Ocular Hypertension treatment market @ Ocular Hypertension Therapeutic Assessment [https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Ocular Hypertension Current Treatment Patterns

4. Ocular Hypertension - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Ocular Hypertension Late-Stage Products (Phase-III)

7. Ocular Hypertension Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Ocular Hypertension Discontinued Products

13. Ocular Hypertension Product Profiles

14. Ocular Hypertension Key Companies

15. Ocular Hypertension Key Products

16. Dormant and Discontinued Products

17. Ocular Hypertension Unmet Needs

18. Ocular Hypertension Future Perspectives

19. Ocular Hypertension Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Ocular Hypertension Pipeline Reports Offerings [https://www.delveinsight.com/report-store/ocular-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ocular-hypertension-pipeline-analysis-2025-by-delveinsight-santen-pharmaceutical-nicox-ophthalmics-inc-allysta-pharmaceuticals-qlaris-bio-inc-ripple-therapeutics-laboratoires-thea-ocular-t]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ocular Hypertension Pipeline Analysis, 2025 by DelveInsight | Santen Pharmaceutical, Nicox Ophthalmics, Inc., Allysta Pharmaceuticals, Qlaris Bio, Inc, Ripple Therapeutics, Laboratoires Thea, Ocular T here

News-ID: 4167144 • Views:

More Releases from ABNewswire

Soft Tissue Sarcoma Clinical Trial Assessment 2025: Investigational Drugs, FDA Approvals, Pipeline Drugs, Therapies, Mechanism of Action, Route of Administration by DelveInsight
Soft Tissue Sarcoma Clinical Trial Assessment 2025: Investigational Drugs, FDA A …
Soft Tissue Sarcoma companies working in the treatment market are Advenchen Laboratories, Philogen, Gradalis, Epizyme, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Incyte Corporation, AVEO Pharmaceuticals, Bayer, Mirati Therapeutics, Novartis, Incyte, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Agenus, Cornerstone Pharmaceuticals, Takara Bio, Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals and others. (Albany, United States) According to DelveInsight, the global Soft Tissue Sarcoma pipeline includes 125+ companies actively developing over 130
NSCLC Clinical Trials Assessment 2025: Therapeutics Landscape, FDA Approvals, Pipeline Analysis, Competitive Landscape, Therapies, Medication, ROA, MOA by DelveInsight
NSCLC Clinical Trials Assessment 2025: Therapeutics Landscape, FDA Approvals, Pi …
NSCLC Companies working in the market include BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, BridgeBio Pharma, Abbvie/Pfizer, Eli Lilly, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre,Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Iovance Biotherapeutics, Galecto Biotech, and others. Non-Small Cell Lung Cancer Clinical Trial Summary The NSCLC pipeline is highly active, with 135+ companies developing 150+
Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook 2034 - Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight
Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook 2034 - Clinical …
CIDP Companies are Takeda, Argenx, Sanofi, Janssen Research and Development, Immunovant Sciences GmbH, HanAll Pharma, Roivant Sciences, Shire, Argenx, Sanofi, Nihon Pharmaceutical, Immunovant Sciences, Octapharma, CSL Behring, Janssen Research, Novartis, Biogen, UCB Biopharma, Takeda, MedDay Pharmaceuticals, Teijin Pharma, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols, Bio Products Laboratory, Baxter, GeNeuro Pharmaceuticals, and others Chronic Inflammatory Demyelinating Polyneuropathy Market Summary The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is set to
Hepatocellular Carcinoma Clinical Trials Assessment 2025: Competitive Landscape, FDA Approvals, Therapies, Emerging Drugs, Mechanism of Action, Route of Administration by DelveInsight
Hepatocellular Carcinoma Clinical Trials Assessment 2025: Competitive Landscape, …
Hepatocellular Carcinoma companies are Polaris Pharmaceuticals, Sumitomo Pharma, Surface Oncology, Oxford BioTherapeutics, OriCell Therapeutics, Tarus Therapeutics, Tvardi Therapeutics, SCG Cell Therapy, AVEO Oncology, Sinocelltech, GlaxoSmithKline, Iterion Therapeutics, Array BioPharma, Beijing SyngenTech, Antengene Corporation, Shenogen Pharma, Novartis Oncology, Eutilex, SillaJen Biotherapeutics, Guangdong ProCap Zoom Biosciences, and Chugai Pharmaceutical. (Albany, USA) According to DelveInsight's analysis, the Hepatocellular Carcinoma (HCC) pipeline Report comprises over 90+ companies developing more than 95+ drug candidates across diverse

All 5 Releases


More Releases for Ocular

How the Ocular Pain Market Is Growing in 2025 | What's New Treatments Are Coming …
According to the IMARC Group, the ocular pain market is expected to exhibit a CAGR of 7.66% during 2025-2035. This can be attributed to the growing use of services in teleophthalmology, which facilitates remote consultations and enhances patient adherence. Ocular pain is the discomfort or distress experienced within or around the eye. The ocular pain market is experiencing significant growth driven by multiple factors. Primarily, the increasing prevalence of conditions such
Key Influencer in the Ocular Implants Market 2025: Growing Geriatric Population …
What market dynamics are playing a key role in accelerating the growth of the ocular implants market? The growth of the ocular implants market is foreseen to be driven by the global increase in the geriatric population. The term 'geriatric population' is specifically used to refer to individuals aged 65 years or above. Ocular implants offer a solution to age-specific eye ailments prevalent among the elderly, such as cataracts, glaucoma, and
Neuropathic Ocular Pain Market Is Booming Worldwide 2025-2032 | OKYO Pharma, Lim …
Latest Report, titled "Neuropathic Ocular Pain Market" Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. The report features a comprehensive table of contents, figures, tables, and charts, as well as insightful analysis. The Neuropathic Ocular Pain market has been
Neuropathic Ocular Pain Market Detailed In New Research Report 2024 |OKYO Pharma …
A recent report from Coherent Market Insight titled "Neuropathic Ocular Pain Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2031" presents a thorough examination of the industry landscape, offering insights into market analysis and trends. Alongside competitor and regional analysis, the report delves into contemporary advancements within the market. Global Neuropathic Ocular Pain market is estimated to be valued at US$ 197.1 million in 2023 and is expected to
Ocular Neuropathic Pain Market to witness Robust Expansion by 2031 - OKYO Pharma …
Ocular neuropathic pain (ONP) is chronic eye pain caused by nerve damage or dysfunction. It can result from various conditions, such as corneal nerve injury, ocular surgeries, infections, or systemic diseases like diabetes. Patients experience persistent, burning, or stabbing eye pain, often without visible signs of inflammation. Diagnosis involves detailed patient history, clinical examination, and sometimes specialized tests. Treatment focuses on managing pain and may include topical or systemic medications,
Ocular Implant Market - Redefining Ophthalmic Solutions: Choose Ocular Implants …
Newark, New Castle, USA: The "Ocular Implant Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Ocular Implant Market: https://www.growthplusreports.com/report/ocular-implant-market/7864 This latest report researches the industry structure, sales, revenue,